Cidara Therapeutics Receives US$20 Million Milestone Payment Following FDA Approval Of Rezzayo
By, Admin1 min read
Share
Cidara Therapeutics, Inc. announced receipt of a US$20 million milestone payment from Melinta Therapeutics following the U.S. Food and Drug Administration (FDA) approval of REZZAYO
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
